Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

ABSTRACT:

Background

Patients diagnosed with high-grade serous ovarian cancer (HGSOC) who received initial debulking surgery followed by platinum-based chemotherapy can experience highly variable clinical responses. A small percentage of women experience exceptional long-term survival (long term (LT), 10+ years), while others develop primary resistance to therapy and succumb to disease in less than 2 years (short term (ST)). To improve clinical management of HGSOC, there is a need to better characterize clinical and molecular profiles to identify factors that underpin these disparate survival responses.

Methods

To identify clinical and tumor molecular biomarkers associated with exceptional clinical response or resistance, we conducted an integrated clinical, exome, and transcriptome a

SUBMITTER: Yang SYC 

PROVIDER: S-EPMC6208125 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature